meta
|
evidence
oncology
Living systematic review and meta-analysis
refractory classic Hodgkin lymphoma (R/R cHL)
R/R cHL - second line or more (L2)
1
colorectal cancer (CRC)
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab alone
versus all
vs immune chekpoint inhibitors
vs others immune checkpoint inhibitors
vs brentuximab vedotin
All patients
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
Statistically conclusive or suggested result
Inconclusive results
Uncertain results
Safety results
R/R cHL - second line or more (L2)
refractory classic Hodgkin lymphoma (R/R cHL)
R/R cHL - second line or more (L2)
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open